RECRUITING

Can Medical Cannabis Affect Opioid Use?

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this observational study is to learn how medical cannabis (MC) affects pain and the use of opioid pain medications. Participants who have chronic pain and use prescribed opioid pain medication will opt-in to using MC or not for the 3-month study. Participants who are certified in Pennsylvania will purchase specific medical cannabis products at a reduced cost from a partnering medical cannabis dispensary monthly. All participants will complete baseline, daily, and monthly assessments to observe changes across groups.

Official Title

The Effect of Medical Cannabis on Opioid Use for Individuals With Chronic Pain

Quick Facts

Study Start:2023-09-07
Study Completion:2025-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06206252

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Current diagnosis of chronic, intractable pain
  2. * Use of prescription opioids for longer than 90 days
  3. * Have a smartphone or agree to use one provided
  4. * English fluency
  5. * Medical cannabis group only: Willing to get certified by a physician to use medical cannabis in PA OR already certified but have not been using medical cannabis products regularly (daily or weekly) for longer than 30 days
  6. * Medical cannabis group only: Willing to accept a temporary restriction on medical cannabis products
  7. * Control group: Agree to continue not using cannabis for the duration of the study (3 months)
  1. * Under 18 years old
  2. * Being under conservatorship
  3. * Self-reported pregnant or breastfeeding
  4. * Cannabis Use Disorder
  5. * Active treatment in methadone or buprenorphine program for Opioid Use Disorder
  6. * Diabetic neuropathy or chemotherapy-induced neuropathy alone
  7. * Medical cannabis group: Cannabis use (daily/weekly) for more than 30 days
  8. * Control group: Cannabis Use

Contacts and Locations

Study Contact

Allison Herens, LSW
CONTACT
215-531-4971
mmjstudy@jefferson.edu

Principal Investigator

Brooke Worster, MD
PRINCIPAL_INVESTIGATOR
Thomas Jefferson University

Study Locations (Sites)

Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107
United States

Collaborators and Investigators

Sponsor: Thomas Jefferson University

  • Brooke Worster, MD, PRINCIPAL_INVESTIGATOR, Thomas Jefferson University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-07
Study Completion Date2025-02

Study Record Updates

Study Start Date2023-09-07
Study Completion Date2025-02

Terms related to this study

Keywords Provided by Researchers

  • Prescription opioids
  • Medical Cannabis

Additional Relevant MeSH Terms

  • Chronic Pain
  • Pain